Loading
Adagene Inc. Stock: price and insider trades · United States
US·Mcap US$153.8M
3 insiders bought €141k of shares over the last 90 days, the latest by Tam Man Kin, filed 25 Sept 2026.
Adagene Inc.: what insiders have been doing
Adagene Inc. is a listed company. Its directors and officers file their transactions with SEC (Form 4). Between 18 October 2025 and 18 October 2026, 5 insiders published 7 filings.
The flow runs one way only: 3 insiders bought (5 purchases totalling €141k) and nobody sold on the market. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Those buying include 1 finance chief, 1 senior executive and 1 chief executive. One trade stands out by size: a purchase of €73k from Luo Peter, disclosed on 6 August 2026, or 0.041% of market capitalisation.
In the case of 2 purchases, another manager of the company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The latest purchase is recent: it was published 23 days ago, on 25 September 2026. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4.
With 7 filings in twelve months, the company is quieter than the median of 19 filings across the 5,811 companies we follow on the same exchange. The full history, which starts in 2026, counts 5 purchases against no sales.
In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
7
Thresholds
n/a
Buy Volume
€140,813
5 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySalePeter Luo3 buys
Cuong do V1 buy
Man Kin Tam1 buy
Since the insiders bought
- -19.7%Entry US$4.12 · Close at T+30 US$3.31
- -15.1%Entry US$4.11 · Close at T+30 US$3.49
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.29
Analyst consensus
6 analysts1.00/5
US$7.00Target US$9.91(+333%)US$17.45
Income statement
RevenueUS$7.7M
EBITDA-US$16.9M-220% margin
Net income-US$17.6M-220.8% margin
Valuation
PER (forward)-5.7x
P/Book1.7x
Beta0.54
Balance sheet & cash
Market capUS$153.8M
Total debtUS$6.3M
Free Cash Flow-US$15.7M
Debt / Equity6%
Profitability & ownership
ROE-28.5%
ROA-14.0%
% insiders11.4%
% institutions36.0%
Last declaration on 25 September 2026
Declarations7 total
2,000 shares@ US$3.000.0030% mcap100.0% of flowAmerican Depositary Shares (ADSs)SEC:0001104659-26-111069:0
Canonical exit: 22 Dec 2026 (T+90)
131,000 shares@ US$3.950.19% mcap100.0% of flowADS EACH REPRESENTING 1.25 ORDINARY SHARES, SOLD TO COVER COSTSEC144:0001104659-26-099289
131,000 shares@ US$3.95ADS EACH REPRESENTING 1.25 ORDINARY SHARES, SOLD TO COVER COSTSEC144:0002108105-26-000001
2,000 shares@ US$3.750.0037% mcap100.0% of flowAmerican Depositary Shares (ADS)SEC:0001104659-26-098426:0
Canonical exit: 12 Nov 2026 (T+90)
7 of 7 declarations
About Adagene Inc.
Adagene Inc. is a biopharmaceutical company focused on developing innovative cancer therapies. It leverages its antibody modification technology platform to enhance treatment efficacy.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
